GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Amarantus Bioscience Holdings AMBS · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 4 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2022

Revenue

$95,331

FY2014FY2022

Net income

−$4.8m

FY2014FY2022

Free cash flow

−$4.5m

FY2014FY2022

Shareholders' equity

−$24.7m

FY2014FY2022

Income statement

Fiscal years

FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Revenue$95,331—$74,700$20.0m—————
Gross profit$95,331—$74,700$20.0m—−$17,240−$58,925−$176,000—
Research and development———$610$1,826$0$3.7m$13.3m$13.8m
Operating income−$268,000−$148,000−$628,000$18.3m−$3.0m−$3.2m−$8.6m−$24.8m−$21.4m
Net income−$4.8m−$10.2m−$628,000$18.4m−$10.6m−$4.4m−$11.6m−$25.2m−$27.3m
Diluted earnings per share-0.01-0.02-0.000.07-0.05-0.07-0.34-1,801.00-4,959.45

Balance sheet

At each fiscal year end

FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Total assets$10.2m$14.7m$24.9m$24.8m$3.5m$10.2m$11.1m$11.8m$2.3m
Cash and short-term investments—$708$46$708$829$47,204$49,221$176,000$214,000
Total liabilities$34.9m$34.6m$34.4m$33.7m$31.4m$28.3m$26.7m$20.5m$6.3m
Debt$19.1m$19.2m$19.2m$19.1m$18.7m$10.7m$11.4m$2.9m$222
Shareholders' equity−$24.7m−$19.9m−$9.5m−$9.0m−$27.9m−$18.0m−$15.6m−$8.7m−$4.1m
Shares outstanding580m465m345m269m234m68m34m0m0m

Cash flow

Fiscal years

FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Cash from operations−$4.5m−$9.9m−$82,662$1.0m−$1.8m−$1.9m−$2.7m−$16.0m−$11.3m
Capital spending—−$5——−$3,456——−$10,000−$181,000
Free cash flow−$4.5m−$9.9m−$82,662$1.0m−$1.8m−$1.9m−$2.7m−$16.0m−$11.5m
Dividends paid———————−$23.4m—

Latest quarters

By quarter end

Mar 2023Dec 2022Sept 2022Jun 2022Mar 2022Dec 2021Sept 2021Jun 2021
Revenue$1,275$23,308$60,937$11,086————
Gross profit$1,275$23,308$60,937$11,086————
Operating income−$60,000−$71,204−$53,640−$86,260−$56,930−$73,870−$38,980−$26,680
Net income−$52,026−$1.4m$336,486−$632,436−$3.1m−$148,871−$10.0m−$18,682
Diluted earnings per share-0.00-0.000.00-0.00-0.01-0.00-0.02-0.00
Cash from operations—−$1.0m——−$3.0m—−$9.0m—
Total assets$10.2m$10.2m$11.6m$11.2m$11.7m$14.7m$14.9m$24.9m
Cash and short-term investments————$32$708$180—
Debt$19.1m$19.1m$19.1m$19.1m$19.2m$19.2m$19.2m$19.2m
Shareholders' equity−$24.7m−$24.7m−$23.3m−$23.6m−$23.0m−$19.9m−$19.5m−$9.4m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-83.2%——
Operating income—-39.2%-23.9%
Net income—1.4%-0.8%

Valuation history

At each fiscal year end

FY2020
Price to sales0.0

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return50%1201%55%-86%114%-51%-29%-82%304%-93%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 150-to-1 reverse split · 10 Jun 2015
  • 25-for-1 split · 14 Jun 2011

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.